Clinical Trials Directory
We are doing this study to see how tucatinib, trastuzumab, and mFOLFOX6 work to treat cancer of your colon or rectum that is HER2-positive with mFOLFOX6 alone or combined with bevacizumab.
We are doing this study to find out if the study intervention (additional delayed MRI sequences) can tell the difference between radiation damage and tumor recurrence.
We are doing this study to learn more about the differences in the muscle and blood of people that have Peripheral Arterial Disease (PAD).
We are doing this study to compare the usual treatment of azacitidine and venetoclax to the combination treatment of azacitidine, venetoclax and gilteritinib. We want to find out if adding gilteritinib to the usual treatment is beneficial for people with acute myeloid leukemia (AML).
We are doing this study to find out if 2 different experimental drug combinations can improve outcomes for people who are newly diagnosed with AML. We want to compare the outcomes from the standard treatment (cytarabine + daunorubicin) to the following experimental regimens:
- Venetoclax + cytarabine + daunorubicin
- Venetoclax + azacitidine
We are doing this study to compare different experimental drug regimens to the usual treatment (cytarabine and daunorubicin) for acute myeloid leukemia (AML). We want to find out which options have the best outcomes. The different drug combinations we will be testing against the usual treatment are:
- daunorubicin and cytarabine liposome
- cytarabine and daunorubicin with venetoclax
- azacitidine and venetoclax
- daunorubicin and cytarabine liposome with venetoclax
We are doing this study to see if blood and bone marrow samples can be tested in a timely manner that allows for the detection of certain markers that could guide cancer treatment.
We are doing this study to better understand nonalcoholic fatty liver disease in people with HIV. We want to find out what are the most accurate, non-invasive diagnostic tests to detect scarring in the liver for people who have HIV. At this time, we do not have a good understanding of the following characteristics of steatotic liver disease in people with HIV:
- Causes of the disease
- Risk factors
- The most accurate, non-invasive tests to measure liver scarring
- How the disease progresses
- Treatment options